---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-032295"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:29:57.734833+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics appoints Dan Weng, M.D. to Board of Directors

## Summary
- Dan Weng appointed as Class II director effective August 18, 2025.
- Dr. Weng has extensive CRO leadership, including CEO of Medelis and former Chairman/CEO of EPS International.
- Appointment supported by parent company GNI Group Ltd. (TSE: 2160).
- He will receive standard non-employee director compensation per company policy.

## SEC filing metadata
- accession: 0001140361-25-032295
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036125032295/0001140361-25-032295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036125032295/ef20054243_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-032295
- JSON: https://secwatch.observer/filing/0001140361-25-032295.json
- Plain text: https://secwatch.observer/filing/0001140361-25-032295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.